MENU
Alnylam

2015 Summer RNAi Roundtable Series

We hosted a series of online “RNAi Roundtables” in July, August and September, at which Alnylam scientists and key clinical collaborators reviewed recent progress in many of the company’s development-stage pipeline programs and discussed the related disease areas.

Click on any of the RNAi Roundtables below to listen to the webcasts and view presentations from these events.

ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders

Wednesday, July 22, 9:00 – 10:30 a.m. ET

  • Benny Sorensen, M.D., Ph.D., Senior Director, Clinical Development
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Margaret Ragni, M.D., M.P.H., Professor of Medicine, Division Hematology/Oncology, University of Pittsburgh, and Director, Hemophilia Center of Western Pennsylvania
  • Guest Speaker: Mark W. Skinner, J.D., Past President, World Federation of Hemophilia/National Hemophilia Foundation

ALN-CC5 for the treatment of Complement-Mediated Diseases
Thursday, July 23, 9:00 – 10:00 a.m. ET 

  • Pushkal Garg, M.D., Senior Vice President, Clinical Development
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Regis Peffault de Latour, M.D., Ph.D., Professor, Hematology and Transplantation, Saint-Louis Hospital, Paris

ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection
Tuesday, July 28, 4:00 – 5:00 p.m. ET

  • Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Edward Gane, MBChB, M.D., FRACP, MNZM, Professor of Medicine, University of Auckland (NZ), and Chief Hepatologist, Transplant Physician, Deputy Director of New Zealand Liver Transplant Unit, Auckland City Hospital

ALN-AAT for the treatment of AAT Deficiency-associated liver disease
Friday, August 14, 2:00 – 3:00 p.m. ET

  • Alfica Sehgal, Ph.D., Principal Scientist, Research
  • Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President of R&D, Chief Medical Officer
  • Guest Speaker: Jeffrey Teckman, M.D., Professor, Department of Pediatrics, St. Louis University School of Medicine

Patisiran and Revusiran for the treatment of Transthyretin (TTR)-Mediated Amyloidosis
Thursday, August 20, 9:00 – 10:30 a.m. ET

  • Eric Green, Vice President, General Manager, TTR Program
  • Jared Gollob, M.D., Vice President, Clinical Research
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Philip Hawkins, Ph.D., FRCP, FRCPath, FMedSci, Head, National Amyloidosis Centre, and Head, Periodic Fever Syndrome Service/Honorary consultant physician
  • Isabelle Lousada, President & CEO, Amyloidosis Research Consortium, and Chairman, Amyloidosis Foundation

ALN-GO1 for the treatment of Primary Hyperoxaluria Type 1 (PH1)
Tuesday, September 8, 9:00 – 10:00 a.m. ET

  • David Erbe, Ph.D., Director, Research
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Sally-Anne Hulton, M.D., FRCPCH, MRCP, FCP, MBBCh, Consultant Paediatric Nephrologist and Clinical Lead, Birmingham Children’s Hospital NHS Trust

ALN-PCSsc for the treatment of Hypercholesterolemia
Wednesday, September 16, 9:30 – 11:00 a.m. ET

  • Kevin Fitzgerald, Ph.D., Vice President, Research
  • David Kallend, MBBS, Vice President and Global Medical Director, The Medicines Company
  • Moderator: Barry Greene, President and Chief Operating Officer
  • Guest Speaker: Marc S. Sabatine, M.D., M.P.H., Chairman, Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women’s Hospital, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, and Professor of Medicine, Harvard Medical School

ALN-AS1 for the treatment of Acute Hepatic Porphyrias
Thursday, September 24, 11:00 a.m. – 12:30 p.m. ET

  • Bill Querbes, Ph.D., Associate Director, Research
  • Moderator: John Maraganore, Ph.D., Chief Executive Officer
  • Guest Speaker: Robert J. Desnick, M.D., Ph.D., Dean for Genetics and Genomic Medicine, Professor and Chair Emeritus, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai Hospital
  • Guest Speaker: Desiree Lyon Howe, Co-Founder and Executive Director, American Porphyria Foundation